oncomouse harvard mouse type laboratory mouse mus musculus genetically modified using modifications designed philip leder timothy harvard university carry specific gene called activated oncogene vharas control mouse mammary tumor virus promoter activated oncogene significantly increases mouses susceptibility cancer thus makes mouse suitable model cancer oncomouse first transgenic mouse developed use cancer research ralph l brinster richard palmiter developed mice previously however oncomouse first mammal patented dupont funded philip leders research harvard university agreed give dupont exclusive rights inventions commercialized result patent applications oncomouse filed back numerous countries united states canada europe european patent office epo japan initially rights oncomouse invention owned dupont however uspto decided final patent actually expired meant oncomouse became free use parties although name oncomouse registered patenting oncomouse significant effect mouse geneticists previously shared information mice colonies openly strain mice first described published research mice stored acquired jackson laboratory nonprofit research institute patenting oncomouse breadth claims made patents considered unreasonable many broadly patenting oncomouse first step shifting academic research away culture open free inexpensive shared resources towards commercial culture expensive proprietary purchase licensing requirements shift felt far beyond mouse genetics community harvard later said regretted handling oncomouse canada supreme court rejected patent harvard college v canada commissioner patents overturning federal court appeal verdict ruled favor patent however october canadian patent ca granted harvard college patent amended omit composition matter claims transgenic mice supreme court rejected entire patent application basis claims canadian patent law allowed amended claims grant rules predated general agreement tariffs trade patent valid european patent application filed june president fellows harvard college initially refused examining division european patent office epo among things grounds european patent convention epc excludes patentability animals per se decision appealed board appeal held animal varieties excluded patentability epc especially article epc animals excluded examining division granted patent publication number ep european patent opposed several third parties precisely opponents notably grounds laid article epc according inventions publication exploitation would contrary ordre public morality excluded patentability oral proceedings took place november patent maintained amended form decision appealed appeal decision taken july case eventually remitted first instance ie opposition division order maintain patent newly amended form however revocation patent eventually published august years filing date normal term european patent article epc failure pay fees file translations amended claims rule epc united states patent trademark office uspto granted us patent filed jun issued apr expired april harvard college claiming transgenic nonhuman mammal whose germ cells somatic cells contain recombinant activated oncogene sequence introduced said mammal claim explicitly excluded humans apparently reflecting moral legal concerns patents human beings modification human genome remarkably us courts called decide validity patent two separate patents issued harvard college covering methods providing cell culture transgenic nonhuman animal us patent filed mar issued feb expired feb testing methods using transgenic mice expressing oncogene us patent filed sep issued jul expires july patents found expire uspto due terminal dupont currentlyneeds update bringing suit eastern district httpsenwikipediaorgwikioncomouse